If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Mounjaro™ (tirzepatide) injection
2.5 mg/5 mg/7.5 mg/10 mg/12.5 mg/15 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
How should tirzepatide doses be increased?
Tirzepatide should be initiated at 2.5 mg subcutaneously once weekly and increased in 2.5 mg increments every 4 weeks until target dose is achieved, up to a maximum dose of 15 mg.
See important safety information, including boxed warning, in the attached prescribing information.
Tirzepatide is a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes (T2D) for once-weekly, subcutaneous administration.1
The recommended starting dose of tirzepatide is 2.5 mg injected subcutaneously once weekly. The 2.5 mg dosage is for treatment initiation and is not intended for glycemic control.1
After 4 weeks, increase the dose to 5 mg once weekly.1
If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose.1
The maximum dose of tirzepatide is 15 mg once weekly.1
- once weekly
- any time of day, and
- with or without food.1
Tirzepatide should be injected subcutaneously in the abdomen, thigh, or upper arm.1
In the phase 3 SURPASS studies, participants were assigned to 1 of 3 tirzepatide treatment arms (5, 10, or 15 mg) for assessment of efficacy and safety ().1
The starting dose of tirzepatide was 2.5 mg once weekly for 4 weeks and escalated in 2.5 mg increments every 4 weeks until the assigned dose was achieved.2
Dose escalation in 2.5 mg increments at 4 week intervals was chosen based on the ability to improve the tolerability profile.2
The 3 tirzepatide doses (5, 10, and 15 mg) studied for efficacy in the SURPASS phase 3 clinical study program were identified based on the safety, efficacy, and exposure response modeling of data in participants with T2D in phase 1 and 2 studies.2
Enclosed Prescribing Information
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
1Mounjaro [package insert]. Indianapolis, IN: Eli Lilly and Company; 2022.
2Conterno E, Yuffa I, Woodward B. Eli Lilly and Company diabetes 2019 business update. Eli Lilly and Company. Published June 10, 2019. Accessed March 22, 2021. https://investor.lilly.com/static-files/a5dbe9fa-f45f-41ef-bc16-bc12be6dd606
Date of Last Review: May 14, 2022